Sino Biopharma’s subsidiary, CTTQ further deepens the exclusive strategic collaboration with GSK: Hong Kong Friday, July 10, 2026, 16:00 Hrs [IST] Sino Biopharmaceutical Limited ...
Sino Biopharmaceutical will receive an upfront payment of $200m from AstraZeneca. The group is also eligible for further ...
In another big-ticket licensing deal with a Chinese biotech, AstraZeneca has claimed rights to a drug candidate for chronic ...
AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results